/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Zyversa Therapeutics Inc share price today is $0.2769, up -43.3%. The stock opened at $0.55 against the previous close of $0.549, with an intraday high of $0.555 and low of $0.27.

style

pb-0

Zyversa Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.2769 -0.433(-43.3%) ZVSA at 13 Mar 2026 04:01 PM Biotechnology

Lowest Today 0.27

Highest Today 0.555

Today’s Open 0.55

Prev. Close 0.549

52 Week High 5.22

52 Week Low 0.27

Day’s Range: Low 0.27 High 0.555

52-Week Range: Low 0.27 High 5.22

Zyversa Therapeutics Inc Institutional Holdings

Zyversa Therapeutics Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Zyversa Therapeutics Inc Fundamentals

Market Cap 2.68 M

PB Ratio 0.3403

PE Ratio 0.0

Enterprise Value -0.36 M

Total Assets 20.60 M

Volume 12453600

Zyversa Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-89561728 -89.6M, FY22:-759097607 -759.1M, FY21:-8905527 -8.9M, FY20:-13199616 -13.2M

Quarterly Revenue Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M, Q1/2024:15600 0.0M, Q4/2023:15600 0.0M

Quarterly Profit Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-2600 -0.0M, Q1/2024:-10439 -0.0M, Q4/2023:13000 0.0M

Quarterly Net worth Q1/2025:-2256930000 -2256.9M, Q3/2024:-2401256000 -2401.3M, Q2/2024:-2763743 -2.8M, Q1/2024:-2826737 -2.8M, Q4/2023:-13338500 -13.3M

About Zyversa Therapeutics Inc & investment objective

Company Information ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.

Organisation Biotechnology

Employees 7

Industry Biotechnology

CEO Mr. Stephen C. Glover

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*